|20/01/16||TGEM038||A novel cell therapy platform to regenerate tubular organs
||Proprietary and biocompatible scaffold (temporary cell delivery device) is combined with a patient’s own cells (haematopoietic stem and precursor cells) to create an esophageal implant that could potentially be used to treat pediatric esophageal atresia and other conditions that affect the esophagus. TGEM038 can also be extended to other tubular organs, including the bronchi and trachea.
|20/01/08||TGEM037||Novel Escherichia coli-Mycobacterium shuttle vector|| TGEM037 has the following strengths compared to other vectors and expected to induce enhanced immune responses.
· High stability and compatibility
· High copy number in mycobacteria
· Stable expression of exogenous genes in mycobacteria
|19/12/24||TGEM036||Proprietary plant-based technology platform for rapid development and production of specialty antibody and protein drugs||The production platform has the following advantages. High yield production of antibodies and proteins, mammalian-type glycosylation (to eliminate the risk of an unwanted immune system reaction), manufacturing products that are hard to express by fermentation, low cost production, etc. The platform has been utilized for production of many antibodies and vaccines.||問合せ|
|19/11/29||TGEM035||Effective platform using highly branched glucan for DDS carrier||Highly branched glucan has very attractive characteristics, such as a spherical nano-sized particle, high water solubility, narrow molecular size distribution, and the numerous modifiable residues, as a dendrimer for pharmaceutical application. Established technology enables to control the average particle size of this glucan between 10 nm and 50 nm strictly, and to conjugate the functional substances, such as peptide, nucleotide, sugar chain, anticancer drug, and antibody, on the surface of its particle arbitrarily. The structural features of this polymer could permit drug delivery to specific tissues and multivalent interactions with target molecules. This glucan is an effective platform for DDS carrier such as vaccine and anticancer drug.||問合せ|
|19/11/05||TGEM034||Innovative platform technology for targeted delivery of therapeutics||A proprietary biomimetic vector (a short peptide that binds to proteoglycan-rich tissues) can be fused with a wide variety of therapeutics (proteins, small molecules etc) and enables delivery of locally injected therapies to the hard-to-reach tissues where they are needed. Sustained therapeutic levels within the targeted tissues can increase efficacy and avoid systemic adverse events.||問合せ|
|19/11/05||TGEM033||Long-term sustained release microformulations||This technology platform enables long-term sustained release of a drug into the blood from the administration site and treatment with once in 1 month to 6 months. The best polymer among more than 15 kinds of polymers can be proposed based on the results of feasibility studies. Opportunity for using this technology is limited to Japanese companies.||問合せ|
|19/09/30||TGEM032||Cell Therapy technology platform for developing cell-based products for multiple chronic diseases
||Novel and propreitary cell therapy platform technology that can be used for the development of cellular therapies. Cellular therapies are the new modality of treatment that provides long-term cures for chronic diseases. This platform can be applied across multiple disease areas-musculoskeletal disorders,urogynacology, oncology,cardiology. Three pronged approach to tackle degenerative diseases through drug/biologic/device mechanisms.||問合せ|
|19/08/21||TGEM031||Delivery of anticancer drugs to cancer cells
||TGEM031 is a modified β-Cyclodextrin and increased in vitro antitumor activities of doxorubicin (DOX), vinblastine and paclitaxel. The complex of DOX with TGEM031 markedly increased antitumor activity of DOX, after intravenous administration to tumor-bearing mice.||問合せ|
|19/07/31||TGEM030||Innovative technology enabling improved GI absorption of the insoluble drug
||A patented technology based on lipidic compositions which form optimal dispersed phase in the gastrointestinal environment for improved absorption of the insoluble drug. TGEM030 enables development of superior oral products with: Improved solubilization and high drug loading capacity, improved bioavailability, faster and more consistent absorption leading to reduced variability and reduced sensitivity to food effects. TGEM030 utilizes bioacceptable excipients and conventional manufacturing processes.
|19/07/08||TGEM029||Sustained release PLGA
||Poly lactide-co-glycolide acid (PLGA) microsphere technology for sustained release of drugs. Versatile drug release profiles could be achieved by adjusting the formulation compositions and effective plasma drug concentration could be maintained for several weeks or months upon one injection. In addition, the pharmacokinetic and pharmacodynamics evaluation models for sustained release technology have been established which could speed up product development.||問合せ|